AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31664452 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 446
Study 31664452 — intervention group
Group type: EXPERIMENTAL
Intervention: QPL intervention (restricted to patients who reviewed the QPL)
Number of subjects: 446
Study 29091001 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-gauge biopsy
Number of subjects: 150
Study 29091001 — intervention group
Group type: COMPARATOR
Intervention: 18-gauge biopsy
Number of subjects: 150
Study 27346646 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (4×4min 90% of peak heart rate; HRpeak)
Number of subjects: 51
Study 27346646 — intervention group
Group type: COMPARATOR
Intervention: MICT (isocaloric at 70% of HRpeak)
Number of subjects: 51
Study 27346646 — intervention group
Group type: COMPARATOR
Intervention: CONT (non-exercise control)
Number of subjects: 51
Study 25397803 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw-retained group (SRG)
Number of subjects: 28
Study 25397803 — intervention group
Group type: COMPARATOR
Intervention: Cement-retained group (CRG)
Number of subjects: 28
Study 25397803 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 23540189 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (200 IU/kg/dose subcutaneously every alternate day for 2 weeks)
Number of subjects: 60
Study 23540189 — intervention group
Group type: COMPARATOR
Intervention: Control (no rHuEPO, received oral iron and folic acid from day 14)
Number of subjects: 60
Study 20590723 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright faces of 5-year-old children, adults, and elderly adults
Number of subjects: 3
Study 20590723 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted faces
Number of subjects: 3
Study 20590723 — intervention group
Group type: EXPERIMENTAL
Intervention: Other-age faces
Number of subjects: 3
Study 18922383 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide 200 mg/day
Number of subjects: 123
Study 18922383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 15795816 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate 10 g daily
Number of subjects: 175
Study 15795816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 12091294 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately early postnatal dexamethasone treatment (4.75 mg/kg over 14 days from the 10th day of life)
Number of subjects: 30
Study 12091294 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 30
Study 10929979 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglactin sutures
Number of subjects: 30
Study 10929979 — intervention group
Group type: COMPARATOR
Intervention: Nylon sutures
Number of subjects: 30
Study 7854168 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human growth hormone (rhGH) at a dose of 0.25 to 0.5 U/kg/wk, administered subcutaneously once a day in the evening.
Number of subjects: 10
Study 7854168 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 10
Study 7854168 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment.
Number of subjects: 10
Study 1835837 — intervention group
Group type: EXPERIMENTAL
Intervention: counseling at the acute stage
Number of subjects: 117
Study 7140140 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking + work
Number of subjects: 0
Study 7140140 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 0
Study 7140140 — intervention group
Group type: EXPERIMENTAL
Intervention: No smoking + work
Number of subjects: 0
Study 7140140 — intervention group
Group type: EXPERIMENTAL
Intervention: No smoking
Number of subjects: 0
Study 31853727 — intervention group
Group type: EXPERIMENTAL
Intervention: Technician-guided ICBT (n = 42)
Number of subjects: 86
Study 31853727 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided ICBT (n = 44)
Number of subjects: 86
Study 29939043 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based mentoring
Number of subjects: 0
Study 29939043 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved relationship quality in mentoring
Number of subjects: 0
Study 30197808 — intervention group
Group type: EXPERIMENTAL
Intervention: Septoplasty
Number of subjects: 50
Study 26848117 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed-sharing 'often'
Number of subjects: 870
Study 26848117 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed-sharing 'intermittently'
Number of subjects: 870
Study 26848117 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed-sharing 'rarely' or 'never'
Number of subjects: 870
Study 26848117 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong prenatal breastfeeding intent
Number of subjects: 870
Study 26848117 — intervention group
Group type: EXPERIMENTAL
Intervention: High prenatal importance to breastfeeding
Number of subjects: 870
Study 24163187 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 0
Study 24163187 — intervention group
Group type: COMPARATOR
Intervention: Gain-framed messages
Number of subjects: 0
Study 24163187 — intervention group
Group type: COMPARATOR
Intervention: No messages
Number of subjects: 0
Study 22108473 — intervention group
Group type: COMPARATOR
Intervention: Compression stockings (group 1)
Number of subjects: 156
Study 22108473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol® (group 2)
Number of subjects: 156
Study 22108473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Pycnogenol® and compression stockings (group 3)
Number of subjects: 156
Study 22108473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol®
Number of subjects: 156
Study 22108473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Pycnogenol® and compression stockings
Number of subjects: 156
Study 22108473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol® plus stockings
Number of subjects: 156
Study 22108473 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 156
Study 22108473 — intervention group
Group type: COMPARATOR
Intervention: Compression stockings and Pycnogenol®
Number of subjects: 156
Study 22108473 — intervention group
Group type: COMPARATOR
Intervention: Laser Doppler flowmetry
Number of subjects: 156
Study 19675206 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 232
Study 17224195 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D intensity modulated radiotherapy (IMRT)
Number of subjects: 306
Study 17224195 — intervention group
Group type: COMPARATOR
Intervention: Standard 2D radiotherapy
Number of subjects: 306
Study 15588339 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) 25 mg qd
Number of subjects: 0
Study 15588339 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) 100 mg qd
Number of subjects: 0
Study 15588339 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) 200 mg qd
Number of subjects: 0
Study 15588339 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) 200 mg bid
Number of subjects: 0
Study 15588339 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) 200 mg qd in HIV-infected patients
Number of subjects: 0
Study 15588339 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) in healthy volunteers
Number of subjects: 0
Study 15588339 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) 200 mg/day
Number of subjects: 0
Study 11907840 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate foam (BMV foam), 0.12%, applied twice daily for 12 weeks
Number of subjects: 40
Study 11907840 — intervention group
Group type: COMPARATOR
Intervention: Placebo foam, applied twice daily for 12 weeks
Number of subjects: 40
Study 9735502 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with protease inhibitors (PI)
Number of subjects: 167
Study 7523961 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 130
Study 3365458 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-212 20 mg
Number of subjects: 8
Study 3365458 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-212 40 mg
Number of subjects: 8
Study 3365458 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-212 (10, 20, 40 mg)
Number of subjects: 8
Study 3365458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31982495 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal imaging at fraction 5 (fx = 5)
Number of subjects: 90
Study 31982495 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal imaging at fraction 10 (fx = 10)
Number of subjects: 90
Study 31982495 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest classifier model
Number of subjects: 90
Study 29940335 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-SMA (shared medical appointments)
Number of subjects: 0
Study 29940335 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 27065472 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS)
Number of subjects: 14
Study 27065472 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Number of subjects: 14
Study 26566367 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTM (recombinant human soluble thrombomodulin)
Number of subjects: 22
Study 26566367 — intervention group
Group type: COMPARATOR
Intervention: non-rhTM (control group)
Number of subjects: 22
Study 23511562 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus aminoglutethimide
Number of subjects: 1509
Study 23511562 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 1509
Study 20457949 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens correction
Number of subjects: 114
Study 20457949 — intervention group
Group type: COMPARATOR
Intervention: Primary intraocular lens (IOL) implantation
Number of subjects: 114
Study 18677672 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthosis provided by the CAD‐CAM method
Number of subjects: 30
Study 18677672 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthosis provided by the foam impression method
Number of subjects: 30
Study 18677672 — intervention group
Group type: COMPARATOR
Intervention: Flat insole
Number of subjects: 30
Study 16945169 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose levamisole combined with 5-FU and leucovorin
Number of subjects: 878
Study 16945169 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose levamisole combined with 5-FU and leucovorin
Number of subjects: 878
Study 14529939 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan 100 mg/m2 (three to four doses at 8- to 12-week intervals)
Number of subjects: 13
Study 14529939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 2 to 4 g/m2 (one or two cycles prior to stem cell collection)
Number of subjects: 13
Study 11099390 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O(2)
Number of subjects: 12
Study 11099390 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CO(2) (with 12% O(2))
Number of subjects: 12
Study 11099390 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 12
Study 9187063 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of the minor premise (not‐q) as the initial premise in modus tollens arguments.
Number of subjects: 0
Study 9187063 — intervention group
Group type: COMPARATOR
Intervention: Inversion of the premise order in modus ponens arguments.
Number of subjects: 0
Study 9187063 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation conditions in modus tollens arguments (Experiments 3 and 4).
Number of subjects: 0
Study 9187063 — intervention group
Group type: COMPARATOR
Intervention: Explicitly stating the not‐q case from the start (Experiments 5 and 6).
Number of subjects: 0
Study 9187063 — intervention group
Group type: COMPARATOR
Intervention: Premise order in conditional fallacies (Experiments 7 and 8).
Number of subjects: 0
Study 1493631 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal splints
Number of subjects: 105
Study 1493631 — intervention group
Group type: COMPARATOR
Intervention: Careful nasal toilet at one week
Number of subjects: 105
Study 4024649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium therapy
Number of subjects: 0
Study 4024649 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31265080 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin prophylaxis
Number of subjects: 0
Study 31265080 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29332308 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous PFO closure
Number of subjects: 3440
Study 29332308 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 3440
Study 27305952 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular meal pattern (6 meals/d)
Number of subjects: 11
Study 27305952 — intervention group
Group type: COMPARATOR
Intervention: Irregular meal pattern (3-9 meals/d)
Number of subjects: 11
Study 24452818 — intervention group
Group type: EXPERIMENTAL
Intervention: Training sessions (1 or 2) for each method of brief preference assessments
Number of subjects: 9
Study 22480341 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation-based intervention delivered by clinic nurse
Number of subjects: 211
Study 22480341 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 211
Study 21210338 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (0.14-0.2 mg/kg daily for 4 days)
Number of subjects: 3
Study 21210338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 4 days)
Number of subjects: 3
Study 17907489 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Bond
Number of subjects: 60
Study 17907489 — intervention group
Group type: COMPARATOR
Intervention: Admira Bond
Number of subjects: 60
Study 17907489 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond
Number of subjects: 60
Study 15071980 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of clinical test results as relative risk reduction
Number of subjects: 96
Study 15071980 — intervention group
Group type: COMPARATOR
Intervention: Presentation of clinical test results as number needed to treat
Number of subjects: 96
Study 11152917 — intervention group
Group type: COMPARATOR
Intervention: 0.625 mg of estrone sulfate + placebo
Number of subjects: 682
Study 11152917 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of estrone sulfate + 2.5 mg medroxyprogesterone acetate
Number of subjects: 682
Study 11152917 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of estrone sulfate + 5 mg medroxyprogesterone acetate
Number of subjects: 682
Study 11152917 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of estrone sulfate + 10 mg medroxyprogesterone acetate
Number of subjects: 682
Study 9421657 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 pitch low mA helical CT
Number of subjects: 25
Study 9421657 — intervention group
Group type: COMPARATOR
Intervention: Conventional high mA CT
Number of subjects: 25
Study 7718382 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.15 mg kg‐1
Number of subjects: 0
Study 7718382 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.2 mg kg‐1
Number of subjects: 0
Study 7718382 — intervention group
Group type: COMPARATOR
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 0
Study 7718382 — intervention group
Group type: COMPARATOR
Intervention: Atracurium
Number of subjects: 0
Study 2715550 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg/day)
Number of subjects: 14
Study 2715550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2715550 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no treatment)
Number of subjects: 14
Study 95729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal luteinising-hormone releasing hormone (L.H.R.H.) administered in six doses daily (1.2 mg/day) for four weeks
Number of subjects: 84
Study 95729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 31868151 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Number of subjects: 0
Study 31868151 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging methods
Number of subjects: 0
Study 31158239 — intervention group
Group type: EXPERIMENTAL
Intervention: R. pomonella
Number of subjects: 61
Study 31158239 — intervention group
Group type: EXPERIMENTAL
Intervention: R. indifferens
Number of subjects: 61
Study 27694436 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW face-to-face (F2F)
Number of subjects: 707
Study 27694436 — intervention group
Group type: COMPARATOR
Intervention: CHW quitline (QL)
Number of subjects: 707
Study 25622080 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic risk information (genetic test/family history)
Number of subjects: 1057
Study 25622080 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 1057
Study 23429094 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment
Number of subjects: 34
Study 23429094 — intervention group
Group type: COMPARATOR
Intervention: Placebo session (deactivated ion generator)
Number of subjects: 34
Study 20666669 — intervention group
Group type: EXPERIMENTAL
Intervention: 532-nm KTP laser irradiation
Number of subjects: 16
Study 20666669 — intervention group
Group type: COMPARATOR
Intervention: 1064-nm Nd:YAG laser
Number of subjects: 16
Study 19309606 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive dynamic hip screw (MIDHS) fixation
Number of subjects: 66
Study 19309606 — intervention group
Group type: COMPARATOR
Intervention: Conventional dynamic hip screw (CDHS) fixation
Number of subjects: 66
Study 17186205 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with access to electronic communication with their GP for a year
Number of subjects: 199
Study 17186205 — intervention group
Group type: COMPARATOR
Intervention: Patients without access to electronic communication with their GP
Number of subjects: 199
Study 16213287 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus + prednisolone
Number of subjects: 21
Study 16213287 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus + mycophenolate mofetil + prednisolone
Number of subjects: 21
Study 16213287 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus + cyclosporine + prednisolone
Number of subjects: 21
Study 16213287 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus
Number of subjects: 21
Study 11962682 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronomodulated chemotherapy (B)
Number of subjects: 0
Study 11962682 — intervention group
Group type: COMPARATOR
Intervention: Standard flat chemotherapy (A)
Number of subjects: 0
Study 10075386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 36
Study 10075386 — intervention group
Group type: COMPARATOR
Intervention: Full night's sleep
Number of subjects: 36
Study 7734897 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term initial hospital stay (23 +/- 4 days)
Number of subjects: 61
Study 7734897 — intervention group
Group type: COMPARATOR
Intervention: Long-term initial hospital stay (9 +/- 3 days)
Number of subjects: 61
Study 7734897 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term initial hospital stay
Number of subjects: 61
Study 7734897 — intervention group
Group type: COMPARATOR
Intervention: Long-term initial hospital stay
Number of subjects: 61
Study 7734897 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment
Number of subjects: 61
Study 2246042 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal iron supplements (oral or parenteral)
Number of subjects: 0
Study 2246042 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral iron
Number of subjects: 0
Study 2246042 — intervention group
Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 0
Study 2246042 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 556551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic polychemotherapy (cyclophosphamide, mercaptopurine, prednisolone, dipyridamol, heparin)
Number of subjects: 55
Study 556551 — intervention group
Group type: COMPARATOR
Intervention: Continuous two-drug regimen (mercaptopurine + prednisolone)
Number of subjects: 55
Study 30019072 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical incision
Number of subjects: 84
Study 30019072 — intervention group
Group type: COMPARATOR
Intervention: Oblique incision
Number of subjects: 84
Study 30019072 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 27848252 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 36
Study 27848252 — intervention group
Group type: COMPARATOR
Intervention: Brochures
Number of subjects: 36
Study 25881677 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan/Naproxen Sodium (S/NS) 85/500 mg
Number of subjects: 94
Study 25881677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 24040080 — intervention group
Group type: EXPERIMENTAL
Intervention: Real TMS
Number of subjects: 0
Study 24040080 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 0
Study 21359633 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention program to prevent disruptive behavior without using restrictive means
Number of subjects: 0
Study 19686744 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal hepatic encephalopathy (mHE)
Number of subjects: 51
Study 19686744 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt hepatic encephalopathy grade I (oHE)
Number of subjects: 51
Study 19686744 — intervention group
Group type: EXPERIMENTAL
Intervention: No hepatic encephalopathy (HE0)
Number of subjects: 51
Study 19686744 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 19686744 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-evaluation questionnaire for mHE and oHE patients
Number of subjects: 51
Study 17873259 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric, verbal, and visual formats of conveying health risks
Number of subjects: 0
Study 17873259 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0